Appropriate Topical Antibiotics for Bacterial Conjunctivitis (Excluding Bactrim)
For bacterial conjunctivitis, use topical fluoroquinolones (moxifloxacin 0.5%, gatifloxacin 0.3%, besifloxacin 0.6%, levofloxacin 0.5%) or non-fluoroquinolone options (erythromycin 0.5% ointment, polymyxin B/trimethoprim drops) as first-line therapy—Bactrim is an oral sulfonamide combination not formulated for ophthalmic use.
Why Bactrim Is Not Used for Bacterial Conjunctivitis
Bactrim (sulfamethoxazole-trimethoprim) is an oral/IV systemic antibiotic 1. It has no FDA-approved ophthalmic formulation and is not indicated for bacterial conjunctivitis 1. Additionally, sulfonamides carry significant hypersensitivity risks including Stevens-Johnson syndrome, toxic epidermal necrolysis, and a characteristic "SCoRCH" syndrome (sudden conjunctivitis, lymphopenia, rash with hemodynamic changes) 2, 3.
Recommended Topical Antibiotics
For Mild Bacterial Conjunctivitis
The 2024 AAO guidelines emphasize that no evidence demonstrates superiority of any particular topical antibiotic 4. Choose based on convenience and cost:
Fluoroquinolones (preferred for broad-spectrum coverage):
- Moxifloxacin 0.5%: 1 drop TID for 7 days—demonstrated noninferior efficacy to levofloxacin with good tolerability 5
- Gatifloxacin 0.3%: 95% total effective rate with broad Gram-positive and Gram-negative coverage 6
- Besifloxacin 0.6%: 1 drop TID (4-12 hours apart) for 7 days—73.3% clinical resolution vs 43.1% placebo, noninferior to moxifloxacin 7
- Levofloxacin 0.5%: Established efficacy comparable to newer fluoroquinolones 5
Non-fluoroquinolone alternatives:
- Erythromycin 0.5% ointment: Standard prophylactic agent, suitable for mild cases 4
- Polymyxin B/trimethoprim combination: Effective option, though moxifloxacin showed superior clinical cure rates in pediatric patients 5
- Tobramycin 0.3%: Effective but less broad-spectrum than fluoroquinolones 8
- Norfloxacin 0.3%: Safe and effective for external ocular infections 8
For Moderate to Severe Bacterial Conjunctivitis
Obtain conjunctival cultures and Gram stain before initiating therapy 4. Start empiric broad-spectrum fluoroquinolone coverage while awaiting results. Consider MRSA coverage in:
- Nursing home residents
- Patients with copious purulent discharge and marked inflammation
- Cases not responding to initial therapy
For MRSA-positive cultures, compounded vancomycin eye drops may be necessary 4.
Critical Clinical Pearls
Treatment Duration
- 5-7 days is standard for uncomplicated cases 4
- Antibiotics provide 26% improvement in clinical cure (68.2% vs 55.5% placebo) by days 4-9 9
- Microbiological cure improves 53% with antibiotics vs placebo 9
When to Avoid Antibiotics
- Viral conjunctivitis will not respond to antibacterial agents 4
- Mild bacterial conjunctivitis is often self-limited in immunocompetent adults 4
- However, antibiotics reduce transmissibility and allow earlier return to school/work 4
Follow-Up Timing
- Return in 3-4 days if no improvement 4
- Consider alternative diagnosis or resistant organisms if worsening
Special Situations Requiring Systemic Therapy
Gonococcal conjunctivitis is the only bacterial conjunctivitis requiring systemic antibiotics—this is a hyperacute, vision-threatening emergency requiring immediate ceftriaxone IM/IV 4. Topical therapy alone is inadequate.
Practical Algorithm
Assess severity: Mild (minimal discharge, mild injection) vs moderate-severe (copious purulent discharge, marked inflammation)
For mild cases: Choose any broad-spectrum topical antibiotic based on cost/availability—fluoroquinolones or erythromycin ointment
For moderate-severe cases:
- Obtain cultures if gonococcal infection suspected
- Start fluoroquinolone drops empirically
- Adjust based on culture results
Consider povidone-iodine 1.25% as alternative when antibiotic access is limited 4
Avoid indiscriminate use to prevent antibiotic resistance 4